Day One Biopharmaceuticals (DAWN) Q3 2025: Ojemda Prescriptions Jump 18%, Deepening Second-Line Standardization
Ojemda’s momentum accelerated in Q3, with new patient starts and broader physician adoption fueling double-digit revenue growth and deepening second-line market penetration. The company raised guidance as durable treatment persistence and favorable payer access reinforce Ojemda’s launch trajectory. Investor focus now shifts to upcoming three-year data and the pipeline’s potential to extend DAWN’s rare oncology franchise.
Summary
- Prescriber Depth Expands: More accounts initiated repeat Ojemda use, strengthening second-line positioning.
- Pipeline Progression: Firefly-2 enrollment and PTK7 ADC advances signal multi-asset growth potential.
- Guidance Raised: Management’s confidence in durable adoption underpins a higher full-year outlook.
Performance Analysis
Net product revenue for Ojemda climbed 15% sequentially in Q3, marking the strongest quarter since launch and bringing year-to-date sales above $102 million. Total prescriptions grew 18% quarter over quarter, with new patient starts accelerating nearly 20%, reflecting not only robust demand but also an expanding prescriber base and increasing treatment persistence. Commercial new patient starts now account for about 90% of active patients, indicating that the launch is transitioning from early access program (EAP) dependence to broad commercial uptake.
Operating discipline was evident, as operating expenses declined for the second consecutive quarter—down 9% versus Q2—even as the company invested in commercial and clinical activities. Ojemda revenue exceeded combined cost of sales and SG&A for the first time, highlighting improving scalability. The company ended the quarter with $451.6 million in cash and no debt, with net cash burn improving as revenue growth outpaced expense increases.
- Second-Line Adoption Surges: Physician-reported second-line use of Ojemda rose more than 60% over the past year.
- Payer Access Remains Strong: About 90% of patients received approval on their first attempt, supporting rapid treatment initiation.
- Persistency Trends Robust: Median duration of therapy in EAP patients reached 20 months, a leading indicator for commercial use.
Gross-to-net was at the high end of the guided 12% to 15% range due to a July price increase and related Medicaid rebate dynamics, but management expects relief in Q4. Channel inventory finished at the low end of the targeted range, attributed to high demand rather than supply constraints.
Executive Commentary
"Q3 was an outstanding quarter for day one. We accelerated growth across every key dimension of Ojemda's performance. New patient starts, total prescriptions, and net product revenue. Our early launch momentum and execution have led to steady and sustainable gains quarter over quarter, reflecting continued performance across the organization and growing confidence in Ojemda's differentiated profile among the members of the PLGG prescribing community."
Dr. Jeremy Bender, Chief Executive Officer
"Additionally, revenue from Ojemda exceeded the combined cost of sales and SG&A for the first time this quarter, highlighting both its growing contribution to the enterprise and the scalability of our operating model. Based on the continued strength of underlying demand and improved visibility into Q4, we are raising our full-year 2025 revenue guidance to a new range of $145 to $150 million."
Charles York, Chief Operating and Financial Officer
Strategic Positioning
1. Ojemda’s Second-Line Standardization
Ojemda, a targeted therapy for BRAF-altered pediatric low-grade glioma (PLGG), is rapidly becoming the preferred second-line treatment. Over 60% of accounts have now treated multiple patients, and the number of accounts treating four or more patients rose 28% quarter over quarter. Management cited strong physician feedback and the impact of new two-year Firefly-1 data, which reinforced both efficacy and reversibility of growth velocity effects, as key drivers of adoption.
2. Durable Treatment Persistence and Breadth
Durable persistence is emerging as a core value lever. EAP patients showed a median duration of 20 months on therapy, with three-quarters of those completing 24 months receiving treatment beyond that window. Commercial persistency data is still maturing, but early signals are consistent. The expanding breadth of prescribing accounts, especially among lower-priority segments, signals continued runway for growth.
3. Pipeline and Portfolio Expansion
DAWN is leveraging its launch platform to build a rare oncology franchise. Firefly-2, a global Phase 3 trial aiming to move Ojemda into frontline use, is on track for full enrollment in the first half of 2026. The PTK7-directed ADC, Day 301, is progressing through dose escalation and optimization, with management expressing confidence in the target’s validity despite broader industry debate. European expansion is also in focus, with a mid-2026 EMA approval decision expected via partner Ipsen.
4. Commercial Model Scalability
Ojemda’s revenue now covers core operating expenses, underscoring the scalability of DAWN’s commercial infrastructure. Management continues to prioritize disciplined capital allocation, with a data-driven approach to investment and expense control. Channel inventory and gross-to-net management remain active levers for operational optimization.
5. Data-Driven Differentiation
Long-term follow-up data is a strategic differentiator. The upcoming three-year Firefly-1 data will provide new insights into post-treatment tumor stability and time to next therapy, key concerns for prescribers. Management expects these data to further distinguish Ojemda from MEK inhibitors, particularly regarding rebound tumor growth and treatment-free intervals.
Key Considerations
DAWN’s Q3 results reflect a business scaling rapidly on the back of a single product, with management executing against clear commercial and clinical priorities while maintaining operational discipline.
Key Considerations:
- Prescriber Expansion Accelerates: Deeper and broader account penetration is driving durable growth, with upside remaining in lower-priority segments.
- Persistence Data Still Maturing: Commercial patient duration signals are not yet fully clear, but EAP trends are encouraging and align with trial benchmarks.
- Gross-to-Net Management in Focus: Price increases and related Medicaid rebates drive temporary gross-to-net pressure, but Q4 relief is expected.
- Pipeline Execution Critical: Continued progress in Firefly-2 and Day 301 will determine multi-asset sustainability beyond Ojemda.
Risks
DAWN’s growth remains highly concentrated in Ojemda, exposing the business to clinical, competitive, and reimbursement risks if persistence or adoption trends falter. Upcoming three-year data could shift prescriber sentiment if rebound tumor growth or shorter-than-expected treatment-free intervals emerge. Pipeline execution, particularly in Firefly-2 and Day 301, is essential to diversify future revenue streams. Reimbursement dynamics, though currently favorable, could tighten if payer policies shift or if competitive therapies gain traction.
Forward Outlook
For Q4, DAWN guided to:
- Continued double-digit sequential Ojemda revenue growth
- Modest increase in operating expenses, reflecting planned commercial and clinical activities
For full-year 2025, management raised guidance:
- Net product revenue of $145 to $150 million
Management highlighted several factors that support the outlook:
- Durable underlying demand and expanding prescriber depth
- Upcoming three-year Firefly-1 data release and European regulatory milestones
Takeaways
DAWN’s Q3 results reinforce the company’s execution strength and the potential for Ojemda to anchor a rare oncology platform, but near-term growth remains singularly dependent on continued adoption and persistence in PLGG.
- Ojemda’s Clinical Profile Drives Adoption: Two-year and soon three-year data are expanding prescriber confidence and deepening market penetration.
- Commercial Model Scales with Demand: Revenue now covers operating costs, with cash reserves providing flexibility for pipeline investment and potential business development.
- Future Results Hinge on Data and Pipeline: Upcoming Firefly-1 and Firefly-2 readouts, as well as Day 301 progress, will shape the company’s trajectory and risk profile.
Conclusion
Day One’s Q3 performance demonstrates robust commercial execution and deepening adoption of Ojemda, underpinned by strong data and disciplined operations. The company’s future will be shaped by upcoming clinical milestones and the ability to extend its rare oncology platform beyond a single product.
Industry Read-Through
DAWN’s rapid Ojemda uptake and prescriber depth expansion highlight the importance of real-world data and long-term clinical follow-up in rare oncology launches. The company’s disciplined expense management and operational scalability offer a blueprint for emerging biotechs seeking to maximize single-product launches. The emphasis on durable persistence and payer access points to critical levers for commercial success in specialty therapeutics. Upcoming three-year data will serve as a key industry benchmark for post-treatment durability and could influence treatment paradigms across pediatric and adult glioma segments.